The Biotechnology Industry Organization this week awarded Alnylam Pharmaceuticals the James D. Watson Helix award for corporate excellence in the emerging/mid-cap category.

The award, presented during BIO's annual CEO and Investor meeting in New York, honors leadership in scientific innovation, company growth, and corporate citizenship. It is presented by the Long Island Life Sciences Initiative, and is jointly sponsored by BIO, Stony Brook University, and The Center for Biotechnology.